The rise of copyright’s blockbuster initially sparked a boom for major pharmaceutical companies, however recent developments present a uncertain outlook for shareholders. Generic alternatives are eroding earnings, https://louisedczi986843.answerblogs.com/41570851/the-blue-pill-and-pharma-a-precarious-play